TY - JOUR
T1 - Leveraging 3D-printed microfluidic micromixers for the continuous manufacture of melatonin loaded SNEDDS with enhanced antioxidant activity and skin permeability
AU - Ongoren, Baris
AU - Kara, Aytug
AU - Casettari, Luca
AU - Tiboni, Mattia
AU - Lalatsa, Aikaterini
AU - Sanz-Perez, Amadeo
AU - Gonzalez-Burgos, Elena
AU - Romero, Alejandro
AU - Juberías, Antonio
AU - Torrado, Juan J.
AU - Serrano, Dolores R.
PY - 2024/7/27
Y1 - 2024/7/27
N2 - Vesicants are chemical warfare agents (CWAs) capable of causing severe skin damage and systemic toxicity. Melatonin, known for its anti-inflammatory and antioxidant properties, can mitigate the effects of these agents. Self-nano-emulsifying drug delivery systems (SNEDDS) containing a high melatonin concentration (5 %, 50 mg/g) were optimized using a quality-by-design approach from biocompatible, non-irritant excipients with a particle size of about 100 nm. The melatonin-loaded SNEDDS showed a 43-fold greater permeability than a conventional melatonin cream. Chemical stability at ambient temperature (25 °C) was maintained for one year. The preparation of optimised melatonin-loaded SNEDDS using a simple mixing method was compared to microfluidic micromixers. Mixing was successfully achieved using a 3D-printed (fused deposition modeling or stereolithography) T-shaped toroidal microfluidic chip (with a channel geometry optimized by computational fluid dynamics), resulting in a scalable, continuous process for the first time with a substantial reduction in preparation time compared to other conventional mixing approaches. No statistically significant differences were observed in the key quality attributes, such as particle size and melatonin loading, between the conventional mixing method in a water bath to reach equilibrium solubility and the use of 3D-printed micromixers. This scalable, continuous, cost-effective approach improves the overall efficiency of SNEDDS production, reduces the cost of quality control for multiple batches, and demonstrates the potential of microfluidic manufacturing with readily customizable 3D-printed micromixers at points of care such as military bases.
AB - Vesicants are chemical warfare agents (CWAs) capable of causing severe skin damage and systemic toxicity. Melatonin, known for its anti-inflammatory and antioxidant properties, can mitigate the effects of these agents. Self-nano-emulsifying drug delivery systems (SNEDDS) containing a high melatonin concentration (5 %, 50 mg/g) were optimized using a quality-by-design approach from biocompatible, non-irritant excipients with a particle size of about 100 nm. The melatonin-loaded SNEDDS showed a 43-fold greater permeability than a conventional melatonin cream. Chemical stability at ambient temperature (25 °C) was maintained for one year. The preparation of optimised melatonin-loaded SNEDDS using a simple mixing method was compared to microfluidic micromixers. Mixing was successfully achieved using a 3D-printed (fused deposition modeling or stereolithography) T-shaped toroidal microfluidic chip (with a channel geometry optimized by computational fluid dynamics), resulting in a scalable, continuous process for the first time with a substantial reduction in preparation time compared to other conventional mixing approaches. No statistically significant differences were observed in the key quality attributes, such as particle size and melatonin loading, between the conventional mixing method in a water bath to reach equilibrium solubility and the use of 3D-printed micromixers. This scalable, continuous, cost-effective approach improves the overall efficiency of SNEDDS production, reduces the cost of quality control for multiple batches, and demonstrates the potential of microfluidic manufacturing with readily customizable 3D-printed micromixers at points of care such as military bases.
KW - melatonin
KW - SNEDDs
KW - topical administration
KW - antioxidants
KW - chemical weapons
KW - 3D prinitng
KW - microfluidic chips
KW - continuous manufacture
U2 - 10.1016/j.ijpharm.2024.124536
DO - 10.1016/j.ijpharm.2024.124536
M3 - Article
SN - 0378-5173
VL - 663
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 124536
ER -